HF
BCAB icon

HRT Financial’s BioAtla BCAB Stock Holding History

HRT Financial’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,095
Closed -$31K – 3796
2025
Q4 		$31K Buy
1,095
+228
+26% +$8.94K ﹤0.01% 2934
2025
Q3 		$29K Buy
867
+452
+109% +$10.4K ﹤0.01% 2660
2025
Q2 		$8K Buy
+415
New +$8.41K ﹤0.01% 2461
2025
Q1 		– Sell
-250
Closed -$7K – 2530
2024
Q4 		$7K Buy
+250
New +$21K ﹤0.01% 2305
2024
Q3 		– Sell
-1,256
Closed -$86K – 2417
2024
Q2 		$86K Buy
+1,256
New +$149K ﹤0.01% 1779
2022
Q3 		– Sell
-2,932
Closed -$417K – 2801
2022
Q2 		$417K Sell
2,932
-1,044
-26% -$166K ﹤0.01% 1800
2022
Q1 		$994K Buy
+3,976
New +$1.66M 0.01% 1040

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial's BCAB Position: Q1 2026 in Review

HRT Financial sold out of BioAtla (BCAB) in Q1 2026, closing a stake of 1,095 shares — an estimated $31K sold.

HRT Financial first reported a position in BCAB in Q1 2022 and held it in 7 quarters. The position peaked at $994K in Q1 2022. 36 funds tracked by Wall St. Rank hold BCAB as of Q1 2026.

  • HRT Financial reported no remaining BioAtla position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 1,095 BioAtla shares in Q1 2026, an estimated $31K.
  • HRT Financial first reported a position in BioAtla in Q1 2022 and held it in 7 quarters.
  • HRT Financial's BioAtla position peaked at $994K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held BioAtla as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.